Related Experiment Video
Updated: Jul 4, 2025
09:51
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells
Published on: June 30, 2023
836
The Golgi Apparatus as an Anticancer Therapeutic Target
Marta Martins1,2, João Vieira1,2, Catarina Pereira-Leite1,3
1CBIOS-Universidade Lusófona's Research Center for Biosciences & Health Technologies, Campo Grande 376, 1749-024 Lisboa, Portugal.
Biology
|January 26, 2024
Summary
The Golgi apparatus (GA) is a promising anticancer target due to its role in cancer progression. Nanodelivery systems offer new strategies to deliver GA-targeted cancer drugs effectively.
Area of Science:
- Cell Biology
- Oncology
- Pharmacology
Background:
- The Golgi apparatus (GA) is crucial for protein and lipid modification and transport, and ion storage.
- GA dysfunction is linked to cancer progression, affecting protein modification, secretion, metabolism, and extracellular environment.
- Despite its potential, few GA-targeted anticancer drugs exist, with none reaching clinical approval.
Purpose of the Study:
- To review current anticancer drugs targeting the Golgi apparatus.
- To explore nanodelivery strategies for enhancing GA-targeted cancer therapy.
- To discuss the benefits and challenges of targeting the GA in cancer treatment.
Main Methods:
- Literature review of existing GA-targeted anticancer drugs.
- Analysis of nanodelivery approaches (passive, active, physical) for GA targeting.
- Discussion of the implications of GA modulation in cancer therapy.
Main Results:
- Limited clinical success of current GA-targeted anticancer drugs.
- Nanodelivery offers potential for improved tumor cell and GA targeting.
- GA dysregulation impacts multiple cancer hallmarks.
Conclusions:
- The Golgi apparatus presents a significant, yet largely untapped, target for cancer therapy.
- Nanotechnology holds promise for overcoming challenges in delivering GA-targeting drugs.
- Further research into GA-targeted therapies and nanodelivery is warranted for effective cancer treatment.
More Related Videos
09:37Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
Published on: August 25, 2021
1.8K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.0K
Related Concept Videos
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
01:49Golgi Apparatus
91.0K
As they leave the Endoplasmic Reticulum (ER), properly folded and assembled proteins are selectively packaged into vesicles. These vesicles are transported by microtubule-based motor proteins and fuse together to form vesicular tubular clusters, subsequently arriving at the Golgi apparatus, a eukaryotic endomembrane organelle that often has a distinctive ribbon-like appearance.
91.0K
01:15Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
02:38Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K